Genmab ADR (NASDAQ: GMAB) established initial surge of 0.21% at $33.72, as the Stock market unbolted on Wednesday, before settling in for the price of $33.65 at the close. Taking a more long-term approach, GMAB posted a 52-week range of $17.24-$33.67.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 28.01%. Meanwhile, its Annual Earning per share during the time was 28.01%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 8.01%. This publicly-traded company’s shares outstanding now amounts to $615.99 million, simultaneously with a float of $615.99 million. The organization now has a market capitalization sitting at $20.77 billion. At the time of writing, stock’s 50-day Moving Average stood at $30.83, while the 200-day Moving Average is $24.89.
Genmab ADR (GMAB) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Genmab ADR industry. Genmab ADR’s current insider ownership accounts for 0.00%, in contrast to 10.31% institutional ownership. According to the most recent insider trade that took place on Dec 18 ’25, this organization’s 10% Owner bought 212,177 shares at the rate of 97.00, making the entire transaction reach 20,581,169 in total value, affecting insider ownership by 71,946,801. Preceding that transaction, on Dec 19 ’25, Company’s 10% Owner bought 66,264 for 97.00, making the whole transaction’s value amount to 6,427,608. This particular insider is now the holder of 72,013,065 in total.
Genmab ADR (GMAB) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.31 per share during the current fiscal year.
Genmab ADR’s EPS increase for this current 12-month fiscal period is 8.01% and is forecasted to reach 1.57 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 6.08% through the next 5 years, which can be compared against the 28.01% growth it accomplished over the previous five years trading on the market.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
Let’s observe the current performance indicators for Genmab ADR (GMAB). It’s Quick Ratio in the last reported quarter now stands at 6.01. Alongside those numbers, its PE Ratio stands at $14.32, and its Beta score is 0.90. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.78. Similarly, its price to free cash flow for trailing twelve months is now 16.63.
In the same vein, GMAB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 2.35, a figure that is expected to reach 0.43 in the next quarter, and analysts are predicting that it will be 1.57 at the market close of one year from today.
Technical Analysis of Genmab ADR (GMAB)
Now, what If we examine the latest scores posted by [Genmab ADR, GMAB]. During the last 5-days, its volume was lower the volume of 1.61 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 97.28% While, its Average True Range was 71.66.
Raw Stochastic average of Genmab ADR (GMAB) in the period of the previous 100 days is set at 98.68%, which indicates a major rise in contrast to 94.48% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.58 that was higher than 0.57 volatility it exhibited in the past 100-days period.
